OSAM
AVTX icon

O'Shaughnessy Asset Management’s Avalo Therapeutics AVTX Stock Holding History

O'Shaughnessy Asset Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-13
Closed -$118K – 906
2018
Q4 		$118K Sell
13
-9
-41% -$100K ﹤0.01% 589
2018
Q3 		$298K Buy
22
+1
+5% +$13.1K 0.01% 463
2018
Q2 		$259K Sell
21
-4
-16% -$47.6K 0.01% 481
2018
Q1 		$315K Buy
+25
New +$282K 0.01% 426

Other funds holding AVTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

O'Shaughnessy Asset Management's AVTX Position: Q1 2019 in Review

O'Shaughnessy Asset Management sold out of Avalo Therapeutics (AVTX) in Q1 2019, closing a stake of 13 shares — an estimated $118K sold.

O'Shaughnessy Asset Management first reported a position in AVTX in Q1 2018 and held it in 4 quarters. The position peaked at $315K in Q1 2018. 31 funds tracked by Wall St. Rank hold AVTX as of Q1 2019.

  • O'Shaughnessy Asset Management reported no remaining Avalo Therapeutics position as of Q1 2019 after selling out during the quarter.
  • O'Shaughnessy Asset Management sold 13 Avalo Therapeutics shares in Q1 2019, an estimated $118K.
  • O'Shaughnessy Asset Management first reported a position in Avalo Therapeutics in Q1 2018 and held it in 4 quarters.
  • O'Shaughnessy Asset Management's Avalo Therapeutics position peaked at $315K in Q1 2018.
  • 31 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2019.

Based on O'Shaughnessy Asset Management's 13F filing for Q1 2019, filed 10 May 2019.